Publications by authors named "Angelo Camporeale"

Claim this Profile
E
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis.
Virginia L Stauffer, Tina M Oakes, Mallikarjuna Rettiganti, Kathleen A Day, Angelo Camporeale

J Neurol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
Virginia L Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Angelo Camporeale

J Headache Pain· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine.
Virginia L Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari, Angelo Camporeale

BMC Neurol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
Tina M Oakes, Richard Kovacs, Noah Rosen, Erin Doty, Phebe Kemmer, Angelo Camporeale

Headache· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke

BMC Neurol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.
Tina Marie Myers Oakes, Vladimir Skljarevski, Qi Zhang, William Kielbasa, Michael E Hodsdon, Angelo Camporeale

Cephalalgia· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Vladimir Skljarevski, Tina M Oakes, Qi Zhang, Margaret B Ferguson, James Martinez, Angelo Camporeale

JAMA Neurol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
Himanshu Upadhyaya, Christopher Kratochvil, Jaswinder Ghuman, Angelo Camporeale, Sarah Lipsius

J Child Adolesc Psychopharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Angelo Camporeale, Vibeke Porsdal, Katrien De Bruyckere, Yoko Tanaka, Himanshu Upadhyaya

J Psychopharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis.
Angelo Camporeale, Kathleen Ann Day, Dustin Ruff, Jody Arsenault, David Williams

Drug Saf· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis